SEARCH

SEARCH BY CITATION

References

  • Akao, Y., Mizoguchi, H., Kojima, S., Naoe, T., Ohishi, N. & Yagi, K. (1998) Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. British Journal of Haematology, 102, 10551060.
  • American Cancer Society. (2006) Cancer Facts and Figures 2006. American Cancer Society, Atlanta.
  • Bellamy, W.T., Dalton, W.S., Gleason, M.C., Grogan, T.M. & Trent, J.M. (1991) Development and characterization of a melphalan resistant human multiple myeloma cell line. Cancer Research, 51, 9951002.
  • Berenson, J.R. (2004) Biology and Treatment of Multiple Myeloma. Humana Press, Totowa, NJ.
  • Berenson, J.R., Boccia, R., Siegel, D., Bozdech, M., Bessudo, A., Stadtmauer, E., Pomeroy, J.T., Steis, R., Flam, M., Lutzky, J., Jilani, S., Volk, J., Wong, S.F., Moss, R., Patel, R., Ferretti, D., Russell, K., Louie, R., Yeh, H.S. & Swift, R.A. (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. British Journal of Haematology, 135, 174183.
  • Berenson, J.R., Matous, J., Swift, R.A., Mapes, R., Morrison, B. & Yeh, H.S. (2007) A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid (ABC) combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Research, 13, 17621768.
  • Campbell, R.A., Manyak, S.J., Yang, H.H., Sjak-Shie, N.N., Chen, H., Gui, D., Popoviciu, L., Wang, C., Gordon, M., Pang, S., Bonavida, B., Said, J. & Berenson, J.R. (2006) LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. International Journal of Oncology, 6, 14091417.
  • Cavigelli, M., Li, W.W., Lin, A., Su, B., Yoshioka, K. & Karin, M. (1996) The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. The EMBO Journal, 15, 62696279.
  • Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P. & Anderson, K.C. (2005) Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics, 4, 686692.
  • Chen, G.Q., Zhu, J., Shi, X.G., Ni, J.H., Zhong, H.J., Si, G.Y., Jin, X.L., Tang, W., Li, X.S., Xong, S.M., Shen, Z.X., Sun, G.L., Ma, J., Zhang, P., Zhang, T.D., Gazin, C., Naoe, T., Chen, S.J., Wang, Z.Y. & Chen, Z. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 88, 10521061.
  • Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 2755.
  • Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J. & Siegel, D.S. (1999) Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by Bcl-2. Blood, 93, 30443052.
  • Friedman, J.M., Ma, M.H., Manyak, S.J., Borad, M.J., Altamirano, C.V., Tang, Y.M., Neeser, J.A., Okopnik, J., Roussos, E., Yang, H., Vescio, R. & Berenson, J.R. (2002) Arsenic trioxide causes apoptosis, growth inhibition and increased sensitivity to chemotherapeutic agents in multiple myeloma cells through inhibition of (NF)-kB activity. Proceedings of the American Association of Cancer Research, 43, 925 (Abstract 4585).
  • Grad, J., Bahlis, N., Reis, I., Oshiro, M., Dalton, W. & Boise, L. (2001) Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 98, 805813.
  • Gupta, V., Singh, S.V., Ahmad, H., Medh, R.D. & Awasthi, Y.C. (1989) Glutathione and glutathione S-transferases in a human plasma cell line selected for resistance to melphalan. Biochemical Pharmacology, 38, 19932000.
  • Han, S.S., Kim, K., Hahm, E.R., Park, C.H., Kimler, B.F., Lee, S.J., Lee, S.H., Kim, W.S., Jung, C.W., Park, K., Kim, J., Yoon, S.S., Lee, J.H. & Park, S. (2005) Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. Journal of Cell Biochemistry, 94, 695707.
  • Hayashi, T., Hideshima, T., Akiyama, M., Richardson, P., Schlossman, R.L., Chauhan, D., Munshi, N.C., Waxman, S. & Anderson, K.C. (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Molecular Cancer Therapeutics, 1, 851860.
  • Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 30713076.
  • Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N.C., Mitsiades, N. & Anderson, K.C. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 15301534.
  • Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L. & Anderson, K.C. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 102, 85678572.
  • Huerta-Yepez, S., Vega, M., Jazirehi, A., Garban, H., Hongo, F., Cheng, G. & Bonavida, B. (2004) Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene, 23, 49935003.
  • Hussein, M.A., Saleh, M., Ravandi, F., Mason, J., Rifkin, R.M. & Ellison, R. (2004) Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 125, 470476.
  • Kapahi, P., Takahashi, T., Natoli, G., Adams, S.R., Chen, Y., Tsien, R.Y. & Karin, M. (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. Journal of Biological Chemistry, 275, 3606236066.
  • Kito, M., Matsumoto, K., Wada, N., Sera, K., Futatsugawa, S., Naoe, T., Nozawa, Y. & Akao, Y. (2003) Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Science, 94, 10101014.
  • Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, JM, Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 11361144.
  • Mathieu, J. & Besançon, F. (2006) Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. International Journal of Cancer, 119, 17231727.
  • May, J.M., Qu, Z., Li, X. (2001) Requirement for GSH in recycling of ascorbic acid in endothelial cells. Biochemical Pharmacology, 62, 873881.
  • Miller, W.H. Jr, Schipper, H.M., Lee, J.S., Singer, J. & Waxman, S. (2002) Mechanisms of action of arsenic trioxide. Cancer Research, 62, 38933903.
  • Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N., Treon, S.P. & Anderson, K.C. (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood, 99, 40794086.
  • Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 23772380.
  • Munshi, N.C., Tricot, G., Desikan, R., Badros, A., Zangari, M., Toor, A., Morris, C., Anaissie, E. & Barlogie, B. (2002) Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 16, 18351837.
  • Niu, C., Yan, H., Yu, T., Sun, H.P., Liu, J.X., Li, X.S., Wu, W., Zhang, F.Q., Chen, Y., Zhou, L., Li, J.M., Zeng, X.Y., Yang, R.R., Yuan, M.M., Ren, M.Y., Gu, F.Y., Cao, Q., Gu, B.W., Su, X.Y., Chen, G.Q., Xiong, S.M., Zhang, T.D., Waxman, S., Wang, Z.Y., Chen, Z., Hu, J., Shen, Z.X. & Chen, S.J. (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 94, 33153324.
  • Rousselot, P., Labaume, S., Marolleau, J.P., Larghero, J., Nogeura, M.H., Brouet, J.C. & Fermand, J.P. (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Research, 59, 10411048.
  • Rousselot, P., Larghero, J., Labaume, S., Poupon, J., Chopin, M., Dosquet, C., Marolleau, J.P., Janin, A., Brouet, J.C. & Fermand, J.P. (2004) Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. European Journal of Haematology, 72, 166171.
  • Soignet, S.L., Frankel, S.R., Douer, D., Tallman, M.S., Kantarjian, H., Calleja, E., Stone, R.M., Kalaycio, M., Scheinberg, D.A., Steinherz, P., Sievers, E.L., Coutre, S., Dahlberg, S., Ellison, R. & Warrell, R.P. Jr. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 38523860.
  • Zhang, W., Ohnishi, K., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Takeshita, K., Takeshita, A. & Ohno, R. (1998) The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia, 12, 13831391.